Organon & Co. (OGN) Expected to Announce Earnings on Thursday

Organon & Co. (NYSE:OGN - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.92 per share and revenue of $1.53 billion for the quarter. Organon & Co. has set its FY 2025 guidance at EPS.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Trading Up 1.9 %

NYSE:OGN traded up $0.25 on Tuesday, reaching $12.97. The stock had a trading volume of 856,771 shares, compared to its average volume of 2,713,837. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The company has a market cap of $3.34 billion, a price-to-earnings ratio of 3.89, a P/E/G ratio of 0.90 and a beta of 0.73. The firm's fifty day moving average is $13.81 and its two-hundred day moving average is $15.11. Organon & Co. has a 12-month low of $10.45 and a 12-month high of $23.10.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 8.64%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is 33.63%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OGN. Barclays decreased their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Finally, Morgan Stanley cut their target price on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $20.60.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.